Upcoming Allied Market Research
Retinal Biologics Market

Retinal Biologics Market: Global Opportunity Analysis and Industry Forecast, 2022-2029 Market

Report Code: A10946
Pages: NA
Nov 2022 | 877 Views
Author(s) : Onkar S
Tables: NA
Charts: NA
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.



Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Retinal Biologics Market

Request Now !

Retinal Biologics Market Outlook - 2027

Retina is a highly sensitive and intricate part of human eye system which functions as a receiver and processor of light and converts it into neural signals and transports it to the brain for visual operation. Retinal function and structured is affected due to disorders related to retina such as diabetic retinopathy, age-related macular degeneration, infectious retinitis, macular edema, retinoblastoma, retinoschisis, retinal degeneration, and other disorders. Whereas, biologics are biotech products often used for therapeutics and are generally produced from microorganisms, or components of animal or plant cells.

Retinal biologics are bioengineered molecules that are implemented in the treatment of various retinal disorders. These biologics are usually implanted in the eyes with intention of treating chronic retinal ailments. Various types of retinal disorders prevail with majority causing visual impairment. The age-related macular degeneration (AMD), is one of the leading cause for blindness among people aged above 50 years. The therapeutics of retinal disorders include various approaches with surgery and medications being the often used approaches.

Market scope and structure analysis:

Report Metric


  Market size available for years


  Base year considered


  Forecast period


  Forecast units

  Value (USD)

  Segments covered

Drug Class, Retinal Disorder Types, Distribution Channels and Region

  Regions covered

•             North America (U.S., Canada, Mexico)

•             Europe (France, Germany, UK, Italy, Spain, Rest of Europe)

•             Asia-Pacific (Japan, China, India, Australia, South Korea, Rest          of Asia-Pacific)

•             LAMEA (Brazil, South Arabia, South Africa, Rest of LAMEA)

  Companies covered

Novartis AG, Regeneron, F. Hoffmann La Roche Ltd, AbbVie Inc., MeiraGTx Limited, OncoGene, Johnson & Johnson (Janssen Pharmaceuticals), Allergan, Bristol-Myers Squibb Company and Oxurion NV.


COVID – 19 scenario analysis: 

  • The COVID-19 pandemic has emerged as a humanitarian as well as economic crisis, creating strain on the society and affecting millions of people and businesses.
  • Industry closures and people are asked to stay in their homes which has taken a huge toll in terms of money and economic growth.
  • Over 4 million people affected globally, with 300 thousand losing their lives due to SARS-CoV-2
  • Healthcare organizations are already working in battle mode, preparing new plans to respond growing COVID-19 patients, right from sourcing rapid diagnosing kits to sufficient PPE kits for workers.
  • Due to diversion of medical field towards treating COVID-19, the funding to R&D activities related to retinal biologics has been reduced and this segment has to face negligence subsequently causing negative impact on retinal biologics market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The growing geriatric population and associated diseases such as age-related macular degeneration (AMD) will serve as a rendering factor stimulating the growth for this market. According to the American Academy of Ophthalmology studies, the number of patients in the U.S. are suffering from AMD is approximately 15 million. The disease have the potential to cause central visual acuity loss in either one or the both eyes in individuals, especially in elderly people. AMD disease advances with growing age, hence the elderly population is at increasing risk. Furthermore, higher frequency of smoking and alcohol consumption paves way for several health issues along with diseases such as hypertension and hypercholesterolemia that will have a positive impact of the retinal biologics industry.

Heavy investments in R&D activities coupled with strategic partnerships between market players to develop retinal biologics will further boost the market growth. Rising prevalence of diabetes will also impact the retinal biologics market growth as diabetes leads to one of the most common retinal disorders, diabetic retinopathy and diabetic macula edema.

On the contrary, the insufficient availability of retinal biologics, harmful after effects of biologics, stringent regulatory compliances imposed by governing authorities associated with biologics approval, and the dearth of accessibility for retinal biologics and efficient therapeutics due to the higher costs may impede the market growth for retinal biologics in the near future.

Technological advances and new product approvals to foster the growth

Major emphasis on R&D associated with retinal therapeutics carried out by various institutions, biologics firms and novel product launches by major market players in the form of biologics and implants would drive the market for retinal biologics in the coming years. Efforts to innovate a parallel therapeutic treatment will further stimulate the market growth.

Approvals by Food and Drug Administration (FDA), the European Medicine Agency (EMA) and the China Food and Drug Administration (CFDA) for innovative products in order to treat retinal diseases will flourish the market. The utilization of anti-VEGF drugs, intravitreal implants and intravitreal injections that release steroids have been approved. VEGF-A antagonist has been emphasized on by key players owing to its abilities of preventing angiogenesis. For instance, Regeneron manufactured Eylea and Roche manufactured Lucentis that is inclusive of anti-VEGF inhibitor, are extensively utilized in the treatment of neovascular age-related macular degeneration (AMD).

Growing prevalence of diabetes to amplify the growth

The growing number of diabetic populace and association of diabetes with retinal disorders has surged the number patients suffering from diabetic retinopathy and diabetic macular edema. Diabetic retinopathy is one of the major cause resulting in loss of vision, around the world. The International Diabetes Federation highlights the destructive consequences of diabetes mellitus would continue to grow as the estimated prevalence of diabetic population to grow from 463 million in 2019 to over 700 million by 2045. Among this patient pool, the individuals suffering from diabetic retinopathy and diabetic macular edema in 2019, was almost 27.0%.

Furthermore, the British Diabetic Association, estimates approximately 3.7 million people in the UK are suffering from diabetes and this number has increased by two times in the last two decades. In addition, almost 12.3 million individuals are potentially at risk of acquiring Type 2 diabetes in the UK. Thus, increasing diabetic population would stimulate the demand for retinal biologics.

Key segments:



  Drug Class

  • TNF-α Inhibitor
  • VEGF-A Antagonist

  Retinal Disorder Type

  • Age-related Macular Degeneration (AMD)
  • Diabetic Retinopathy (DR)
  • Diabetic Macular Edema (DME)
  • Macular Hole
  • Uveitis
  • Others

  Distribution Channel

  • Hospitals
  • Retail Pharmacies
  • Specialty Ophthalmology Clinics


  • North America
  • Europe
  • Asia-Pacific

Key benefits of the report:

  • This study presents the analytical depiction of the global retinal biologics market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global retinal biologics market share.
  • The current market is quantitatively analyzed from 2020 to 2027 to highlight the global retinal biologics market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global retinal biologics market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the retinal biologics market research report:

  • Which are the leading market players active in the retinal biologics market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

Retinal Biologics Market: Global Opportunity Analysis and Industry Forecast, 2020-2027 Report Highlights

Aspects Details
By Drug Class
  • TNF-α Inhibitor
  • VEGF-A Antagonist
By Retinal Disease Type
  • Age-related Macular Degeneration (AMD)
  • Diabetic Retinopathy (DR)
  • Diabetic Macular Edema (DME)
  • Macular Hole Uveitis
  • Others
By End User
  • Hospitals
  • Specialty Ophthalmology Clinics
  • Retail Pharmacies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, Italy, UK, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players Novartis AG, Regeneron3F, Hoffmann La Roche Ltd, AbbVie, Inc3 MeiraGTx Limited3, OncoGene3, Johnson & Johnson (Janssen Pharmaceuticals), Allergan, Bristol-Myers Squibb Company, Oxurion NV.
Other Players Pfizer Inc

Loading Table Of Content...

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Retinal Biologics Market

Start reading.
This Report and over 19,297+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise

  • $9,870
  • Unlimited
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
  • Company Profiles
  • Newly Added Content Access
  • 10 PDF
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD


Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers